Amgen is laying off 380 people from its research and development division, reports Fierce Biotech. The layoffs will be mainly in the US, with 226 people being let go from the company's Thousand Oaks location, with others from Seattle, South San Francisco, Boston, and possibly in the UK. Fierce Biotech notes that while the layoffs represent 2 percent of the company's overall workforce, they are 6 percent of its R&D staff. "These are very targeted and strategic reductions so we can continue to allocate our R&D resources in a focused manner," says Amgen spokesperson Mary Klem, according to Reuters.